INVESTOR NEWS

Jan 22, 2021

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..

Dec 15, 2020

Gentian Diagnostics presents at the DNB Nordic Healthcare Conference

Moss, 15.12.20

Dec 14, 2020

Gentian and research partners with two posters related to the value of calprotectin in management of COVID-19 patients at the AACC

Moss, 14.12.2020

Dec 09, 2020

Financial Calendar

Financial calendar for Gentian Diagnostics AS

Nov 20, 2020

New study results confirm the value of calprotectin in management of COVID-19 patients

Moss, Norway 20.11.2020 Gentian Diagnostics AS is pleased to announce that the results from a study conducted..

Nov 05, 2020

Gentian Diagnostics divests its subsidiary PreTect AS

Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS to Mel-Mont Medical, Inc...

Oct 29, 2020

Third quarter 2020 financial report

Moss, 29 October 2020

Oct 22, 2020

Presentation of 2020 third quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2020 third quarter results on October 29th at 10.00 am.

Sep 02, 2020

Gentian Diagnostics presents at the Pareto Healtcare conference

Moss 02.09.20

Aug 27, 2020

STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19

Moss, 27.08.20